Inlyta 1mg Tablet 28's
₹6844.5*
MRP ₹8347
18% off
₹7095*
MRP ₹8347
15% CB
₹1252 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Inlyta 1mg Tablet is an anti-cancer medicine used in the treatment of renal cell carcinoma. Renal cell carcinoma, also known as kidney cancer, is a disease in which the cancer or malignant cells grow uncontrollably in the kidney and form a tumour.
Inlyta 1mg Tablet contains Axitinib as an active ingredient, which belongs to the class of medicines known as kinase inhibitors. It works by inhibiting the action of an enzyme (tyrosine kinase) and thus stops the abnormal growth of cancer cells.
Inlyta 1mg Tablet may cause certain side effects such as diarrhea, rash, tiredness, decreased appetite, nausea, vomiting, increased blood pressure, muscle cramps, chest pain, weakness, dizziness, hoarseness, and constipation. Inform your doctor if any of these side effects bother you. Inlyta 1mg Tablet should be taken as advised by your doctor.
Avoid taking Inlyta 1mg Tablet if you are allergic to it or any other components of it. Before taking Inlyta 1mg Tablet , inform your doctor if you have/had liver or kidney disease, gastrointestinal disorders, heart problems, thyroid disorders, or blood disorders. This medicine is known to cause embryo-fetal toxicity. Hence, it is not recommended for use in pregnancy and breastfeeding.
Inlyta 1mg Tablet contains Axitinib, which is used in treating advanced renal cell carcinoma after failure of prior systemic therapy. It works by stopping the action of a tyrosine kinase enzyme that causes the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other parts of the body. It also decreases the blood supply to cancer tumors to slow down the growth of the tumor. In this way, Inlyta 1mg Tablet stops the body's production, spread and growth of cancerous cells.
To treat your condition effectually, continue taking Inlyta 1mg Tablet for the period that your doctor has prescribed. Avoid taking Inlyta 1mg Tablet if you are allergic to it or any other components present in it. Caution should be exercised if you have/had liver or kidney disease, any planned surgery, heart disease, stroke, blood or bleeding disorders, or gastrointestinal disorders. Inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment as this medicine is known to cause embryo-fetal toxicity. Breastfeeding should be discontinued in nursing mothers during the treatment as it passes into breast milk and may cause a possible risk to the infant. Avoid driving and operating machines, as this medicine may cause visual disturbances. This medicine is not recommended for use in children below 18 years of age as the safety and efficacy are not established. Inlyta 1mg Tablet may cause hypertension, arterial and venous thrombotic events, hemorrhagic events, hypothyroidism, gastrointestinal perforation and fistula, Reversible Posterior Leukoencephalopathy Syndrome (RPLS), elevated liver enzymes in some patients. Hence, inform your doctor about your complete medication and medical history before taking Inlyta 1mg Tablet .
Drug-Drug Interactions: Inlyta 1mg Tablet may have interaction with strong CYP3A4/5 inhibitors (clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, ritonavir), strong CYP3A4/5 inducers (carbamazepine, rifampicin, phenytoin, phenobarbitone, dexamethasone).
Drug-Food Interactions: Avoid alcohol consumption and smoking.
Dug-Disease Interactions: Tell your doctor if you have liver or kidney disease, heart problems, GI perforation, lung toxicity, thyroid dysfunction, or thromboembolism before starting the treatment.
Renal Cell Carcinoma: Also known as kidney cancer. It is the most common type of cancer seen in adults. This condition occurs when cancer/ malignant cells grow uncontrollably in the kidney and form a tumor. Advanced kidney cancer (metastatic renal cell carcinoma) occurs when the malignant cells spread to other parts of the body. Symptoms include red, orange, or pink-coloured urine due to the presence of blood in the urine.
Alcohol
Caution
Limit alcohol consumption while taking Inlyta 1mg Tablet .
Pregnancy
Unsafe
Inlyta 1mg Tablet is not recommended for use in pregnancy as it may cause embryo-fetal toxicity and harm your foetus. Hence, if you are pregnant or planning pregnancy, inform your doctor before taking Inlyta 1mg Tablet . You should not become pregnant while you are taking Inlyta 1mg Tablet . Using effective birth control methods while on treatment with Inlyta 1mg Tablet is suggested.
Breast Feeding
Caution
It is not known whether Inlyta 1mg Tablet passes into breastmilk. Hence, if you are breastfeeding, inform your doctor before taking Inlyta 1mg Tablet . Your doctor may prescribe this medicine if the benefits outweigh the risks.
Driving
Unsafe
Inlyta 1mg Tablet may cause dizziness and visual disturbances in some patients. Hence, do not drive, operate machinery, or engage in any activity that needs clear vision until you are confident that you can do so safely while you are on treatment with Inlyta 1mg Tablet .
Liver
Caution
If you have a pre-existing or a history of liver problems, tell your doctor before taking this medicine. Inlyta 1mg Tablet is known to cause elevated liver enzymes, which may be fatal. Hence, this medicine should be taken cautiously in patients with moderate liver impairment. Your doctor may suggest tests to monitor your liver function while on treatment with this medicine.
Kidney
Caution
If you have a pre-existing or a history of kidney diseases, inform your doctor before taking Inlyta 1mg Tablet . Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.
Children
Unsafe
Inlyta 1mg Tablet is not recommended for use in children below 18 years of age as the safety and efficacy is not established.
Country of origin
Manufacturer/Marketer address
Product Substitutes